子宫内膜聚质转化为子宫内膜癌的危险因素:从文献计量分析的见解
Aijie Xie1, Xian Wu1, Yunyi Su1
1Department of Obstetrics and Gynecology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617 Ri Yue Street, Chengdu, 610091, Sichuan, China.
Journal of health, population, and nutrition
|March 29, 2025
概括
了解子宫内膜聚合体 (EP) 到子宫内膜癌 (EC) 的进展至关重要. 关键的风险因素包括年龄和更年期状态,建议长期治疗和多角切除术.
科学领域:
- 妇科 妇科医生 妇科
- 在瘤学瘤学.
- 图书统计学 图书统计学
背景情况:
- 子宫内膜聚合体 (EP) 存在转化为子宫内膜癌 (EC) 的风险.
- 子宫内膜癌严重影响妇女的生活质量,并造成大量的财务成本.
- 识别EP转化为EC的风险因素对于预防至关重要.
研究的目的:
- 将EP转换为EC的风险因素的已发表文献的特征映射出来.
- 通过图书统计分析,了解该领域的研究前沿和热点.
主要方法:
- 来自网络科学核心集合 (1996-2024) 的数据.
- 使用CiteSpace,R包Bibliometrix和在线计量平台进行的分析.
- 包括90篇关于EP到EC转换的风险因素的出版物.
主要成果:
- 美国妇产产科杂志是最有成效的期刊.
- 关键的研究术语包括透镜,绝经后妇女,绝经前状态,治疗,诊断,他莫西芬使用,超声波和管理.
- 长期管理EPs成为新的研究热点.
结论:
- 年龄,绝经前期,绝经后出血,PCOS和多体大小是经常研究的危险因素.
- 对于高危患者,可能会建议进行子宫内膜多角切除术和长期管理策略.
更多相关视频
相关概念视频
Disorders of the Female Reproductive System
200
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
200
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Cancer Survival Analysis
291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K


